Fusion of the Paired Box 3 (PAX3) and Myocardin (MYOCD) Genes in Pediatric Rhabdomyosarcoma

被引:2
作者
Panagopoulos, Ioannis [1 ]
Gorunova, Ludmila [1 ]
Andersen, Kristin [1 ]
Lund-Iversen, Marius [2 ]
Tafjord, Svetlana [2 ]
Micci, Francesca [1 ]
Heim, Sverre [1 ,3 ]
机构
[1] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Genet & Informat, Sect Canc Cytogenet, POB 4954 Nydalen, NO-0424 Oslo, Norway
[2] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, Oslo, Norway
[3] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway
关键词
Pediatric; rhabdomyosarcoma; chromosome translocation; PAX3; MYOCD; PAX3-MYOCD fusion gene; BIPHENOTYPIC SINONASAL SARCOMA; FOXO TRANSCRIPTION FACTORS; ALVEOLAR RHABDOMYOSARCOMA; N-MYC; TUMOR; TRANSLOCATION; DIFFERENTIATION; EXPRESSION; RECURRENT; PROLIFERATION;
D O I
10.21873/cgp.20293
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Fusions of the paired box 3 gene (PAX3 in 2q36) with different partners have been reported in rhabdomyosarcomas and biphenotypic sinonasal sarcomas. We herein report the myocardin (MYOCD on 17p12) gene as a novel PAX3-fusion partner in a pediatric tumor with adverse clinical outcome. Materials and Methods: A rhabdomyosarcoma found in a 10-year-old girl was studied using a range of genetic methodologies. Results: The karyotype of the tumor cells was 48,XX,add(2)(q11),+del(2)(q35),add(3)(q?25),7,del(8)(p21),-15,add(17)(p11 ),+20,+ der( ?)t(?;1 5) (?;q15),+mar[8]/46,XX[2]. Fluorescence in situ hybridization detected PAX3 rearrangement whereas array comparative genomic hybridization revealed genomic imbalances affecting hundreds of genes, including MYCN, MYC, FOXO3, and the tumor suppressor gene TP53. A PAX3-MYOCD fusion transcript was found by RNA sequencing and confirmed by Sanger sequencing. Conclusion: The investigated rhabdomyosarcoma carried a novel PAX3-MYOCD fusion gene and extensive additional aberrations affecting the allelic balance of many genes, among them TP53 and members of MYC and FOXO families of transcription factors.
引用
收藏
页码:723 / 734
页数:12
相关论文
共 50 条
  • [41] Pax3 inhibits Neuro-2a cells proliferation and neurite outgrowth
    Huo, Bingqing
    Yang, Yang
    Li, Manhui
    Wan, Jun
    Zhang, Wei
    Yu, Bo
    Chen, Xiaofan
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021, 25 (02) : 1252 - 1262
  • [42] PAX3 is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells
    Xia, Liang
    Huang, Qingfeng
    Nie, Dekang
    Shi, Jinlong
    Gong, Mingjie
    Wu, Bin
    Gong, Peipei
    Zhao, Longxiang
    Zuo, Hao
    Ju, Shaoqin
    Chen, Jian
    Shi, Wei
    BRAIN RESEARCH, 2013, 1521 : 68 - 78
  • [43] Sinonasal alveolar rhabdomyosarcoma with PAX3::NCOA1 fusion expressing SOX10 and with nodal metastases: a double diagnostic pitfall
    Crane, Hannah
    Young, Robin J.
    Fernando, Malee S.
    Griffin, Jon
    JOURNAL OF CLINICAL PATHOLOGY, 2024,
  • [44] Pax3 loss of function delays tumour progression in kRAS-induced zebrafish rhabdomyosarcoma models
    Kahsay, A.
    Rodriguez-Marquez, E.
    Lopez-Perez, A.
    Hornblad, A.
    von Hofsten, J.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [45] PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification
    Missiaglia, Edoardo
    Williamson, Dan
    Chisholm, Julia
    Wirapati, Pratyaksha
    Pierron, Gaelle
    Petel, Fabien
    Concordet, Jean-Paul
    Thway, Khin
    Oberlin, Odile
    Pritchard-Jones, Kathy
    Delattre, Olivier
    Delorenzi, Mauro
    Shipley, Janet
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) : 1670 - 1677
  • [46] Questionable Universal Validity of PAX3/FOXO1 Fusion Gene Status As Molecular Marker for Improvement of Risk Stratification in Rhabdomyosarcoma Therapy
    Stegmaier, Sabine
    Bielack, Stefan S.
    Leuschner, Ivo
    Klingebiel, Thomas
    Koscielniak, Ewa
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (32) : 4039 - 4040
  • [47] KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma
    Sobral, Lays M.
    Hicks, Hannah M.
    Parrish, Janet K.
    McCann, Tyler S.
    Hsieh, Joseph
    Goodspeed, Andrew
    Costello, James C.
    Black, Joshua C.
    Jedlicka, Paul
    MOLECULAR ONCOLOGY, 2020, 14 (10) : 2471 - 2486
  • [48] Co-expression of alternatively spliced forms of PAX3, PAX7, PAX3-FKHR and PAX7-FKHR with distinct DNA binding and transactivation properties in rhabdomyosarcoma
    Du, SY
    Lawrence, EJ
    Strzelecki, D
    Rajput, P
    Xia, SJ
    Gottesman, DM
    Barr, FG
    INTERNATIONAL JOURNAL OF CANCER, 2005, 115 (01) : 85 - 92
  • [49] Retention of Pax3 Expression in Satellite Cells of Muscle Spindles
    Kirkpatrick, Lisa J.
    Yablonka-Reuveni, Zipora
    Rosser, Benjamin W. C.
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2010, 58 (04) : 317 - 327
  • [50] PAX3 in neuroblastoma: oncogenic potential, chemosensitivity and signalling pathways
    Fang, Wen-Hui
    Wang, Qiuyu
    Li, Hong-Mei
    Ahmed, Mashud
    Kumar, Patricia
    Kumar, Shant
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2014, 18 (01) : 38 - 48